The Novel Actions of the Metabolite GnRH-(1-5) are Mediated by a G Protein-Coupled Receptor by Darwin Omar Larco et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HYPOTHESIS ANDTHEORY ARTICLE
published: 08 July 2013
doi: 10.3389/fendo.2013.00083
The novel actions of the metabolite GnRH-(1-5) are
mediated by a G protein-coupled receptor
Darwin Omar Larco1, Nina Nashat Semsarzadeh2, Madelaine Cho-Clark 2, Shaila K. Mani 3,4 and
T. JohnWu1,2*
1 Program in Molecular and Cellular Biology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2 Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA
4 Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA
Edited by:
Pei-SanTsai, University of Colorado,
USA
Reviewed by:
Deborah Mary Power, Universidade
do Algarve, Portugal
Wilson Chung, Kent State University,
USA
*Correspondence:
T. JohnWu, Department of Obstetrics
and Gynecology, Uniformed Services
University, 4301 Jones Bridge Road,
Bethesda, MD 20814, USA
e-mail: tao-yiao.wu@usuhs.edu
The gonadotropin-releasing hormone (GnRH) was originally isolated from the mammalian
hypothalamus for its role as the primary regulator of reproductive function. Since its discov-
ery, GnRH has also been shown to be located in non-hypothalamic tissues and is known
to have diverse functions. Although the regulation of GnRH synthesis and release has
been extensively studied, there is additional evidence to suggest that the processing of
GnRH to the metabolite GnRH-(1-5) represents another layer of regulation. The focus of
this review will be on the current evidence for the action of the pentapeptide metabolite
GnRH-(1-5) in regulating cellular migration. We discuss the potential role of GnRH-(1-5) in
regulating GnRH neuronal migration during development. Furthermore, we demonstrate
these actions are mediated by the activation of a G protein-coupled receptor. Our find-
ings suggest that GnRH-(1-5) may play a developmental function in addition to regulating
developing cells.
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INTRODUCTION
The regulation of reproductive function is dependent on the
proper coordination between the three axes of reproduction: the
hypothalamus, anterior pituitary, and the gonads [hypothalamic-
pituitary-gonadal (HPG) axis]. Gonadotropin-releasing hormone
(GnRH) is a key regulator of this axis and thus of reproductive
function and behavior. GnRH has 23 known isoforms, which
are present in both mammalian and non-mammalian species
(1). The N- and C-terminal sequences of GnRH, pGlu-His-Trp-
Ser, and Pro-Gly NH2 respectively, have been highly conserved
throughout evolution reinforcing the essential role GnRH plays in
reproduction (1).
Neurons that synthesize GnRH are widely distributed in the
basal forebrain and project to the median eminence where GnRH
is released in a pulsatile manner into the hypophyseal portal
vessels. Secreted GnRH stimulates the synthesis and secretion
of the gonadotropins, luteinizing hormone (LH), and follicle-
stimulating hormone (FSH), in the anterior pituitary. These
gonadotropins subsequently exert their effects at the gonadal level
to regulate the secretion of steroid hormones. In the female, LH
and FSH act on the ovary to facilitate follicular maturation and
to regulate the secretion of estrogen and progesterone, which
act as feedback modulators of the hypothalamic-pituitary axis.
Estrogen has been shown to both stimulate and inhibit GnRH
release depending on the stage of the estrus cycle (2–4). Fur-
thermore, GnRH can regulate its own synthesis and secretion via
an autocrine mechanism, which can be influenced by other neu-
ropeptides (5, 6). Despite significant research clarifying the HPG
axis, the integration of signals required for normal function of the
GnRH neuroendocrine axis is not completely understood.
In our previous work, we have shown that the metabolite of
GnRH,GnRH-(1-5), is biologically active and may serve as another
regulatory factor of the HPG axis. It has been established that
GnRH neurons originate outside of the central nervous system
(CNS) and migrate to its final position in the basal forebrain
(7, 8). Along this migratory pathway, GnRH is cleaved by the
zinc metalloendopeptidase EC 3.4.24.15 (abbreviated EP24.15),
to generate GnRH-(1-5) (9–11). Although neuropeptidases have
been thought to degrade proteins to cease further peptide action,
GnRH-(1-5) has been shown to facilitate reproductive behavior
(12) and to increase GnRH mRNA levels (13). More recently,
GnRH-(1-5) was demonstrated to inhibit the migration of GN11
cells, a GnRH secreting cell line, by binding the G protein-coupled
receptor (GPCR), GPR173 (14). These biologically active roles of
GnRH-(1-5) may implicate the peptide as a regulator of the HPG
axis rather than simply a metabolic byproduct.
DEVELOPMENT OF THE GnRH NEUROENDOCRINE SYSTEM
Initial studies by Schwanzel-Fukuda demonstrated that GnRH
neurons originate outside the CNS in the nasal region (15). Sub-
sequent studies validated these observations showing that GnRH
neurons migrate from the nasal placode traversing the cribriform
plate to target the basal forebrain (7, 8). In the developing mouse,
GnRH immunoreactivity is detected as early as embryonic day
(ED) 10.5 in the vomeronasal region (15). By ED 15, most GnRH
neurons have already migrated along vomeronasal tract to the
prepoptic area (7, 15). A subpopulation of GnRH positive cells are
localized in the tectum near the mesencephalic vesicle peaking at
ED 15; however, they cease to exist in the adult and their func-
tion has not been elucidated (16). The primary GnRH neuronal
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population in adulthood is estimated to be near 800 cells distrib-
uted throughout the basal forebrain (7, 8, 17). Figure 1A shows the
GnRH neuronal migratory route during different developmental
stages in the mouse. At approximately ED 15.5, most GnRH neu-
rons have crossed the cribriform plate into the basal forebrain.
Interestingly, GnRH positive cells near the nasal region migrate
radially, which is in contrast to their tangential migratory pat-
tern once these neurons are in the CNS (Figure 1B). The proper
migration of GnRH neurons during development requires the
integration of multiple guidance cues in part mediated through
the activation of certain GPCRs including prokineticin receptor-
2 (PROKR2) (18), and CXCR4 (19). Additionally, the migratory
rate of GnRH neurons seems to be another layer of regulation as
there is a brief delay in migration as they begin to traverse the
cribriform plate to enter the CNS. This delay may serve to aid in
the transition between the nasal region and the CNS to properly
respond to a changing microenvironment and migratory trajec-
tory (20). A more comprehensive overview of the development of
the GnRH neuroendocrine system can be found in the reviews in
(21) and (22).
HYPOGONADOTROPIC HYPOGONADISM
Defects in the HPG axis lead to the development of various types
of hypogonadotropic hypogonadism (HH) where the onset of
puberty and fertility are impaired. There are a number of genes
implicated in the pathogenesis of HH, including mutations in the
genes encoding the GnRH peptide and its receptor. Mutations
associated with these genes are generally classified as normosmic
HH (nHH) where GnRH signaling is impaired yet olfactory senses
remain intact (23). Other forms of HH exist where patients suf-
fer from reduced olfaction in addition to deficiencies in pubertal
development and fertility. This form of HH also called Kallmann
Syndrome (KS) is attributed to a defect in GnRH neuronal migra-
tion. Specifically, precursor olfaction and GnRH neurons emanat-
ing from the olfactory placode remain arrested in the cribriform
plate during development, never entering the CNS to reach their
target sites (24). Patients diagnosed with nHH or KS have reduced
levels of circulating gonadotrophins, LH, and FSH, which would
normally stimulate the secretion of steroid hormones from the
testes or ovaries. In turn, these patients suffer from delayed puber-
tal onset and reduced gonadal function among other pathologies
(23, 25–28).
Recent studies focusing on the molecular basis for KS impli-
cate genes believed to aid in both the origination and migration
of GnRH neurons during development such as FGFR1, FGF8, and
KAL1 (29). Disruption of FGFR1 signaling was demonstrated to
lead to the development of KS (30). FGFR1 and its ligand are
required for the proper birth and maintenance of GnRH neurons
FIGURE 1 | Gonadotropin-releasing hormone neuronal migratory route
during development. (A) GnRH neurons are born in the nasal placode near
the vomeronasal organ (VMO) at approximately embryonic day (ED) 11.5 in the
mouse. As development progresses GnRH neurons begin to enter the CNS
(dashed lines) at ED12.5 and begin to descend within the basal forebrain
region at ED15.5. (B) Most GnRH neurons are within the CNS at ED15.5
however the remaining GnRH neurons in the nasal septum (NS) have a
morphologically distinct migratory pattern relative to neurons found near the
telencephalon (tel). Arrow indicates descending GnRH neurons of a mouse
ED15.5 brain (Wu, TJ unpublished data). LTV, left telencephalic vesicle; OB,
olfactory bulb; OE, olfactory epithelium; PIT, pituitary; MV, mesencephalic
vesicle; T, tectum.
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during embryogenesis; knockdown of both genes results in the
absence of GnRH neurons (31). In addition to the complete
absence of GnRH neurons, disruption of neuronal migration has
also been identified as a cause of KS. Observation of a Kallmann’s
fetal brain revealed GnRH and olfactory neurons resided in the
nasal cavity and failed to cross the cribriform plate to enter the CNS
(32). This improper migration of GnRH neurons was attributed
to the deletion of the KAL1 gene located on the X chromosome
at Xp22.3. More recently, in vitro studies indicate the product of
KAL1 acts as a chemoattractant for immortalized premigratory
GnRH neurons (33) by associating with cell surface heparin sul-
fate proteoglycans (34). Interestingly,many signaling cues required
for normal GnRH neuronal migration require the activation of
GPCRs including PROKR2, which has been linked to the develop-
ment of KS (35). Mutations localized in the intracellular loop 1 of
PROKR2 have been identified in patients with KS and is attributed
to aberrant receptor membrane localization and receptor activity
(36). However, complete identification of all factors contributing
to the proper migration of GnRH neurons is still limited since the
majority of KS cases have yet to be linked to a genetic defect (37).
Patients with nHH harboring mutations in genes encoding
GnRH or its receptor GnRHR do not have obvious anatomi-
cal aberrations of the hypothalamus that would suggest a defect
in neuronal migration; yet they continue to suffer from delayed
pubertal development. Recently, a frameshift mutation in the
GnRH gene was identified in teenage siblings who had intact olfac-
tion but suffered from underdeveloped gonadal function. GnRH
treatment in one of the siblings increased circulating LH levels
(38, 39), indicating that the GnRHR was responsive to exogenous
GnRH administration. These findings are recapitulated in studies
using the hypogonadal (HPG) mouse where the GnRH gene is
no longer expressed; however still retain the ability to respond
to exogenous GnRH (40, 41). Furthermore, HPG mice receiv-
ing preoptic transplantations containing GnRH neurons induced
episodic LH secretion; thus rescuing the knockout phenotype and
indicating that the developmental expression of GnRH is not
required for a functional GnRH pulse generator (42).
Apart from defective GnRH gene expression, a significant num-
ber of other patients with nHH have been shown to contain various
types of mutations in the gene encoding its receptor the GnRHR
leading to complete or partial loss of receptor activity (23, 43,
44). Like the HPG mouse, GnRHR deletion in mouse models dis-
rupts pubertal onset and gonadal function; yet, exogenous GnRH
treatment does not rescue the phenotype and demonstrates that
GnRH function requires proper GnRHR signaling (45). Further-
more, these studies paralleled observations seen in patients with
nHH linked to defective GnRHR activity where the distribution of
GnRH neurons in the brain was normal (45). In terms of recep-
tor activity, the severity of hypogonadism in patients depends on
the specific mutation within the GnRHR gene (46, 47). In cer-
tain cases low levels of pulsatile LH secretion are detected whereas
others are completely unresponsive to exogenous GnRH admin-
istration and thus gonadotropin levels are absent (43). Future
studies will need to address the functional relevance of the spe-
cific GnRHR mutations to potentially develop therapeutics that
may overcome or ameliorate the reproductive deficits observed in
these patients.
GnRH METABOLISM
A number of neuropeptides can undergo enzyme-mediated
processing – whether intracellularly or extracellularly – leading to
different functional roles. For example, the precursor polypeptide
proopiomelanocortin (POMC) can undergo several intracellular
post-translation modifications (PTM) that give rise to different
mature peptides such as ACTH, α-MSH, and β-endorphin (48).
Although these peptides are synthesized from the same parent
peptide they do not necessarily mediate the same functions. Fur-
thermore, their processing is dependent on the tissue where they
are expressed (49). Similarly, the prepro-GnRH undergoes sev-
eral intracellular modifications before giving rise to the mature
form of the GnRH peptide. The prepro-GnRH is 92 amino acids
with an N-terminal signal sequence that is removed to gener-
ate the pro-GnRH peptide. The decapeptide GnRH is located
closer to the N-terminus while the C-terminal region contains the
GnRH-associated peptide (GAP). Both fragments are separated
by a cleavage site that allows for further processing to generate the
mature forms of the GnRH and GAP peptides (50) (Figure 2).
The function of GAP is not clear but it has been shown to regulate
prolactin, LH, and FSH secretion (51). Furthermore, it is possi-
ble GAP is metabolized into smaller peptide fragments that have
biological activity; however this remains to be determined.
The previous notion that neuropeptidases in the extracellular
milieu degrade peptides to cease further biological activity has
been modified due to the growing evidence that suggests other-
wise (11, 52, 53). Metabolized peptide products have been shown
to regulate a variety of functions independent of the parent pep-
tide. For example, the C-terminal fragments degraded from the
full-length arginine vasopressin have no effect on water reten-
tion but modulate learning behavior and memory formation (54,
55). Furthermore, there is evidence suggesting that metabolized
fragments can regulate a more specific function from that of
the parent peptide. This is the case for bradykinin-(1-5), which
only inhibits thrombin-induced platelet aggregation, but does not
induce vasodilation like its parent peptide bradykinin (56). Collec-
tively, these findings highlight another level of complexity where
peptidases can be viewed as activating enzymes that participate in
the regulation of a wide variety of processes in the CNS.
In the extracellular matrix, GnRH is metabolized by the
zinc metalloendopeptidase, EC 3.4.24.25 (EP24.15) (Figure 2).
EP24.15, also commonly referred to as thimet oligopeptidase, is
a hydrolase (3), which acts on peptide bonds (4) requiring Zn2+
as a coactivator (24) and thiol-mediated activation (15). EP24.15
is most prominently expressed in the brain, testis, and pituitary
gland. Enzymes in this family contain the HEXXH motif in the
active site common in zinc metallopeptidases and are known to
hydrolyze peptide bonds in substrates less than 40 amino acids
in length (52). EP24.15 has specificity for substrates less than 17
amino acids long and prefers substrates with hydrophobic residues
at the P1, P2, and P3′ positions (52, 57). Regulation of EP24.15
enzymatic action is regulated by various mechanisms including
thiol activation (58) and phosphorylation (59). Although some
members of the family are membrane-bound, EP24.15 lacks a
transmembrane domain and is primarily found in a soluble form
in both the brain and periphery. EP24.15 has also been observed
to have an extracellular association with the plasma membrane
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FIGURE 2 | Gonadotropin-releasing hormone Peptide Processing. The prepro-GnRH is processed intracellularly to generate the mature GnRH peptide. In
the extracellular matrix, GnRH is metabolized in a two step mechanism generating the metabolite GnRH-(1-5). Modified from Roberts et al. (11).
where it displays ectoenzymatic activity (60). Despite this finding,
analysis of the EP24.15 cDNA sequence does not contain a motif
indicative of a plasma membrane association (60). Further exam-
ination of EP24.15 associating with the extracellular face of the
plasma membrane revealed that it localizes with lipid rafts (61).
This localization with lipid rafts could produce a microenviron-
ment in which EP24.15 can readily access its substrates, including
GnRH, and alter signaling pathways (61).
To ensure the proper hydrolysis of GnRH to produce GnRH-
(1-5), EP24.15 requires both zinc in its active site and protein
kinase A (PKA). PKA phosphorylates EP24.15 at serine residue
644, which actually decreases the enzyme’s affinity for GnRH.
Despite its reduced affinity, when EP24.15 does bind GnRH, it
produces substrate very rapidly (59). This mechanism suggests
that the enzyme can handle large concentrations of peptide with-
out becoming saturated, which is important due to the pulsatile
nature of GnRH release (53, 59). In addition to the activation of
the enzyme, GnRH must also assume a specific conformation to
properly dock at the active site of EP24.15. The N- and C-terminus
of the pentapeptide come together to assume a βII’-type turn con-
formation. It has been shown that the sixth amino acid residue
of GnRH, a highly conserved glycine, is essential for this folding.
When the sixth residue is replaced by with d-amino acids, as in
GnRH analogs like leuprolide, the peptide is no longer hydrolyzed
by EP24.15 and GnRH-(1-5) is not produced. The full-length
GnRH is metabolized in a two-step mechanism. First, the glycine
residue at the 10th position is removed by a prolyl endopeptidase
to generate GnRH-(1-9). Subsequently, EP24.15 cleaves GnRH-
(1-9) at the 5th and 6th position thereby forming the metabolite
GnRH-(1-5) (52, 58, 62) (Figure 2).
Apart from GnRH processing, EP24.15 is also involved in the
metabolism of other peptides including bradykinin, neurotensin,
and angiotensin I, which may produce different biological out-
comes (53, 63). For example, EP24.15 cleaves angiotensin I to
angiotensin-(1-7), which has the opposite effect on blood pres-
sure relative to his parent peptide (63). This finding suggests that
EP24.15 can process various peptides that can oppose the actions
of the parent peptide. Similarly, we have shown that GnRH-(1-
5) stimulates GnRH mRNA expression in GnRH neurons while
treatment with the full-length GnRH inhibits its expression (13).
Therefore in mammals EP24.15 may have a role in regulating
reproductive behavior by processing GnRH to GnRH-(1-5). In a
previous study, we have shown immunoneutralization of EP24.15
in animals treated centrally with GnRH reversed the ability of
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GnRH to facilitate lordosis behavior in the female rat. Further-
more, female rats treated with GnRH-(1-5) facilitated the lordosis
response (12), suggesting that this behavior can indirectly be reg-
ulated by EP24.15 via of its processing of GnRH to form the
bioactive GnRH-(1-5). This is further reinforced by evidence indi-
cating that exposure to the steroid hormone estrogen regulates
EP24.15 levels in brain regions implicated in reproductive func-
tion such as the ventromedial nucleus of the hypothalamus (64)
and in the lateral external layer of the median eminence where
GnRH neurons terminate (8). Collectively, these studies suggest
that EP24.15 is an important processor of GnRH to form the
bioactive GnRH-(1-5).
GnRH-(1-5)-MEDIATED ACTIVATION OF GPR173
The endopeptidase EP24.15 is expressed early in development
along the GnRH migratory path where the levels of GnRH-(1-
5) have been detected (9). Thus the availability of GnRH-(1-5)
and its localization with immature GnRH neurons suggest that
it may play a regulatory role in the migration of GnRH neurons
prior to entering the CNS through the cribriform plate. We have
previously demonstrated that GnRH-(1-5), generated by EP24.15
activity, has functional roles by stimulating GnRH mRNA expres-
sion in immortalized GnRH neurons (13); and facilitating lordosis
behavior in rodents (12). However, the role of GnRH-(1-5) during
development specifically on GnRH neurons has not been estab-
lished. Recently, we implicated GnRH-(1-5) as regulator of GnRH
neuronal migration using the immortalized GnRH secreting cell
line, the GN11 cell, as an in vitro model (14). We demonstrated
that GnRH-(1-5) inhibited GN11 cellular migration via the acti-
vation of GPR173 (14). Physiologically this finding may in part
contribute to the brief delay observed in the migration rate of
GnRH neurons as they begin to transition into the CNS (20).
In addition to our findings, it is plausible that a physical barrier
such as the cribriform plate impedes the migration of the GnRH
neurons. Also, changes in the ECM or surrounding cells could be
another justification for the decrease in migration. For example,
it has been demonstrated that GABAergic signaling from sur-
rounding neurons inhibits GnRH neuronal movement in the nasal
compartment (65). Regardless, our studies implicate an endoge-
nous ligand for the orphan receptor GPR173 indicating that the
delay in migratory rate may indeed serve an important function to
potentially aid in GnRH neuronal maturation or to facilitate the
proper coordination of these neurons to their targets within the
CNS (20).
Our previous work and unpublished observations suggest that
GPR173 levels are developmentally regulated specifically in sites
of GnRH-(1-5) action including the nasal region of embryonic
mice (14) and in the hypothalamus. Additionally, these findings
are in accord with high-throughput expression and in situ analy-
ses demonstrating the presence of GPR173 is enriched in these
regions relative to other sites in the brain and in the periphery (66,
67). GPR173 belongs to a small subfamily of GPCRs known as the
Super Conserved Receptor Expressed in Brain (SREB) family. Only
two other SREB proteins have been identified: GPR27 and GPR85
(68). The SREB proteins are expressed primarily in the brain and
genital organs (68). Functional studies reveal that GPR27 regu-
lates the production of insulin (69, 70) while GPR85 is thought to
play a role in neurogenesis (71). Although no known ligands have
been found to activate the SREB receptors with GPR173 as the
exception, they are thought to be aminergic receptors due to their
sequence similarity to other such GPCRs (68). This is an interest-
ing concept since GnRH-(1-5) is a pentapeptide with an imidazole
functional group provided by the second N-terminal amino acid
histidine, which may play a role in the activation of GPR173.
One of the most intriguing aspects of GPR173 is its con-
servation among vertebrate species. Orthologs of GPR173 have
been identified in rats, mice, bovine, and the zebrafish species
(Figure 3). At the mRNA level, the protein-coding regions of
many species share a significant degree of homology relative to
the human GPR173 (Table 1). Similarly, analysis of the human,
mouse, rat, and zebrafish orthologs of GPR173 show a high degree
of conservation and reveal similar putative sites of PTM (Figure 4).
Like other highly conserved proteins, this degree of conservation
throughout evolution suggests an imperative physiological pur-
pose. GnRH is a neuropeptide that has been conserved throughout
evolution in both vertebrates and invertebrates and is known to
be essential to reproduction in vertebrates – a function, without
which, there would be no propagation (72). The conservation
FIGURE 3 | Putative mRNA Structure of GPR173 across Species.
Analysis of the putative GPR173 mRNA structure across species reveals a
significant degree of conservation within the coding region. These
structures were generated from NCBI website (Bethesda, MD, USA). The
mRNA accession number can be found inTable 1.
www.frontiersin.org July 2013 | Volume 4 | Article 83 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Larco et al. GnRH-(1-5) regulates cellular migration
Table 1 | Percent homology of the GPR173 mRNA sequence across species.
Mouse NM_027543.3 Rat NM_022255.1 Bovine NM_001015604.1 Zebrafish NM_131498.1
Human NM_018969.5 (%) 95 95 95 77
The percent homology was calculated using the coding region of the putative GPR173 mRNA sequence of each species relative to the human sequence.
Sequence information and the calculation of homology were obtained from the NCBI website (http:// www.ncbi.nlm.nih.gov/ pubmed) and the NCBI Blast website
(http:// blast.ncbi.nlm.nih.gov/ Blast.cgi ), respectively. The NCBI accession ID is indicated below each species.
HUMAN MAN--------------TTGEPEEVSGALSPPSASAYVKLVLLGLIMCVSLAGNAILSLL 46
MOUSE MAN--------------TTGEPEEVSGALSLPSASAYVKLVLLGLIMCVSLAGNAILSLL 46
RAT   MAN--------------TTGEPEEVSGALSLPSASAYVKLVLLGLIMCVSLAGNAILSLL 46
BOVINE MAN--------------TTGEPEEVSGALSPPSAVAYVKLVLLGLIMCVSLAGNAILSLL 46
ZEBRAFISH MANGNASSDGPGNPLAAVVSTTGGVMGGAPSSAVSTYVKLVLLGLIICISLVGNLVVSLL 60
*** ...    * *.    :. :**********:*:**.** ::***
HUMAN VLKERALHKAPYYFLLDLCLADGIRSAVCFPFVLASVRHGSSWTFSALSCKIVAFMAVLF 106
MOUSE VLKERALHKAPYYFLLDLCLADGIRSAICFPFVLASVRHGSSWTFSALSCKIVAFMAVLF 106
RAT VLKERALHKAPYYFLLDLCLADGIRSAICFPFVLASVRHGSSWTFSALSCKIVAFMAVLF 106
BOVINE VLKDRALHKAPYYFLLDLCLADGIRSAVCFPFVLASVRHGSSWTFSALSCKIVAFMAVLF 106
ZEBRAFISH VLRDRALHKAPYYFLLDLCLADTIRSAVCFPFVLVSIKNGSAWTYSVLSCKVVAFMAVLF 120
**::****************** ****:******.*::.**:**:*.****:********
HUMAN CFHAAFMLFCISVTRYMAIAHHRFYAKRMTLWTCAAVICMAWTLSVAMAFPPVFDVGTYK 166
MOUSE CFHAAFMLFCISVTRYMAIAHHRFYAKRMTLWTCAAVICMAWTLSVAMAFPPVFDVGTYK 166
RAT CFHAAFMLFCISVTRYMAIAHHRFYAKRMTLWTCAAVICMAWTLSVAMAFPPVFDVGTYK 166
BOVINE CFHAAFMLFCISVTRYMAIAHHRFYAKRMTLWTCAAVICMAWTLSVAMAFPPVFDVGTYK 166
ZEBRAFISH CFHAAFMLFCISVTRYMAIAHHRFYSKRMTFWTCVAVVCMVWTLSVAMAFPPVFDVGTYK 180
*************************:****:***.**:**.*******************
HUMAN FIREEDQCIFEHRYFKANDTLGFMLMLAVLMAATHAVYGKLLLFEYRHRKMKPVQMVPAI 226
MOUSE FIREEDQCIFEHRYFKANDTLGFMLMLAVLMAATHAVYGKLLLFEYRHRKMKPVQMVPAI 226
RAT FIREEDQCIFEHRYFKANDTLGFMLMLAVLMAATHAVYGKLLLFEYRHRKMKPVQMVPAI 226
BOVINE FIREEDQCIFEHRYFKANDTLGFMLMLAVLMAATHAVYGKLLLFEYRHRKMKPVQMVPAI 226
ZEBRAFISH FIREEDQCIFEHRYFKANDTLGFMLMLAVLILATHVVYMKLLLFEYKHRKMKPVQMVPAI 240
******************************: ***.** *******:*************
HUMAN SQNWTFHGPGATGQAAANWIAGFGRGPMPPTLLGIRQNGHAASRRLLGMDEVKGEKQLGR 286
MOUSE SQNWTFHGPGATGQAAANWIAGFGRGPMPPTLLGIRQNGHAASRRLLGMDEVKGEKQLGR 286
RAT SQNWTFHGPGATGQAAANWIAGFGRGPMPPTLLGIRQNGHAASRRLLGMDEVKGEKQLGR 286
BOVINE SQNWTFHGPGATGQAAANWIAGFGRGPMPPTLLGIRQNGHAASRRLLGMDEVKGEKQLGR 286
ZEBRAFISH SQNWTFHGPGATGQAAANWIAGFGRGPMPPTLLGIRQNLHNQNRRLLGMEEFKAEKQLGR 300
************************************** *  .******:*.*.******
HUMAN MFYAITLLFLLLWSPYIVACYWRVFVKACAVPHRYLATAVWMSFAQAAVNPIVCFLLNKD 346
MOUSE MFYAITLLFLLLWSPYIVACYWRVFVKACAVPHRYLATAVWMSFAQAAVNPIVCFLLNKD 346
RAT MFYAITLLFLLLWSPYIVACYWRVFVKACAVPHRYLATAVWMSFAQAAVNPIVCFLLNKD 346
BOVINE MFYAITLLFLLLWSPYIVACYWRVFVKACAVPHRYLATAVWMSFAQAAVNPIVCFLLNKD 346
ZEBRAFISH MFYVITLFFLVLWSPYIVACYWRVFVKACTIPHRYLSTTVWMSFAQAGVNPIICFFLNKD 360
***.***:**:******************::*****:*:********.****:**:****
HUMAN LKKCLRTHAPCWGTGGAPAPREPYCVM 373
MOUSE LKKCLRTHAPCWGTGGAPAPREPYCVM 373
RAT LKKCLRTHAPCWGTGGAPAPREPYCVM 373
BOVINE LKKCLRTHAPCWGTGGAPAPREPYCVM 373
ZEBRAFISH LKKGLLAHLPPCCRTPPQLPREPYCVM 387
*** * :* *         ********
FIGURE 4 | GPR173 Protein Sequence Alignment. A protein sequence
analysis of GPR173 reveals a high degree of conservation across species.
Additionally, many sites within the intracellular loop 3 are putative
phosphorylation sites (yellow) with a conserved lysine residue (purple), which
may undergo ubiquitination. A highly conserved arginine residue (green) in the
N-terminal tail indicates a putative site for N-glycosylation. “*” indicate
conserved residues; “.” or “:” indicate similarity between residues. Shaded
regions indicate putative transmembrane spanning domains (TM). Sequence
alignment analysis was conducted by using the UniProt consortium
(www.uniprot.org).
of GPR173 throughout the evolution of vertebrates suggests its
function to be important, if not indispensible.
Using a bioinformatic approach, we examined the GPR173
sequence for likely PTM sites that regulate receptor activity
and function. There are seven putative phosphorylation sites
(Figure 4), many of which are in the large third cytoplasmic loop
(Figure 5). This is of significance since phosphorylation typically
negatively regulates GPCRs by desensitization and endocytosis,
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FIGURE 5 | Putative Model of Mouse GPR173 Disposition in the Membrane. The structure sketch map of Mouse GPR173 shows a large intracellular loop
with multiple sites that may undergo post-translational modification. Yellow denotes putative phosphorylation site; purple denotes putative ubiquitination site;
and green denotes putative N-glycosylation site. This model of GPR173 was generated with the aid of the UniProt consortium (www.uniprot.org).
best exemplified by the β-adrenergic receptor (βAR). Upon epi-
nephrine binding to the βAR, a cascade of events occur that
lead to sequential activation of PKA, β-adrenergic receptor kinase
(βARK), and the receptor internalization and desensitization (73–
75). The mechanism of internalization typically involves the
recruitment of adaptor proteins such asβ-arrestin initially believed
to solely mediate GPCR internalization. However, recent evidence
suggests β-arrestin may play a more diverse function in regulating
GPCR function. For example, the activation of the parathyroid
hormone receptor 1 (PHR1) leads to the formation of a complex
consisting of PHR1, β-arrestin, and Gβγ subunits to enhance
cAMP formation rather than cease receptor activity (76). Addi-
tionally, βAR has also been shown to deviate from the GPCR
canonical signaling pathway to recruit β-arrestin and c-Src subse-
quently leading to the activation of the ERK pathway (77). Whether
any of the potential sites within the intracellular loops of GPR173
are indeed phosphorylated remains to be determined; however, the
high degree of conservation of these motifs across species indicates
they may play a role in receptor function (Figure 4). Mutagenesis
studies will be instrumental in examining the role played by each
of these motifs and how they regulate GPR173 activity in response
to GnRH-(1-5) during development and in adult function.
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Another potential site for PTM within the accessible areas of
GPR173 is an asparagine residue in the extracellular N-terminal
tail (Figure 5). This site is a candidate for N-glycosylation, which
may facilitate receptor interaction with the extracellular milieu or
assist in ligand recruitment. Previous studies have identified two
glycosylation sites (Asn4 and Asn18) within the GnRHR to be
critical for receptor expression and stability in the plasma mem-
brane (78). Additionally, N-glycosylation sites on the Luteinizing
Hormone Receptor (LHR) at Asn173 and Asn152 were demon-
strated to be essential in the binding of LH to its receptor (79).
Lastly, there is a lysine in the third cytoplasmic loop that could
potentially be a target of ubiquitination (Figure 5). Ubiquitina-
tion has long been associated with the down regulation of GPCR
activity via receptor endocytosis and degradation, but recent stud-
ies suggest that ubiquitination plays a role in the trafficking and
positive regulation of certain GPCRs (80). In some instances,
ubiquitination-mediated internalization of GPCRs facilitates the
formation of complexes important in propagating a signal rather
than ceasing activity (80). This is best exemplified by the co-
internalization of the angiotensin (AT1A) receptor and activated
pERK-1/2 into an endosome to allow for sustained activity of
pERK-1/2 (80). Whether this type of regulation or any of the PTMs
mentioned are related to GPR173 function and activity remains to
be addressed.
Our previous work implicates the GnRH metabolite GnRH-
(1-5) in the regulation of GnRH neuronal migration. The
GnRH-(1-5) mechanism is complex involving the interaction of
other growth factors, which serve to stimulate migration. This
cooperation between stimulators of migration and the inhibitory
action of GnRH-(1-5) is likely important at the region separating
the nasal compartment from the CNS where there is a brief delay
in GnRH neuronal migration. GnRH-(1-5) binding to GPR173
may serve to modulate the migratory rate of GnRH neurons to
potentially prime them for entry into the CNS or to facilitate the
maturation of these neurons. Our understanding of the mech-
anism responsible for the integration of all signaling inputs to
properly establish the GnRH neuronal population in the basal
forebrain remains to be completely elucidated. Our studies on
GnRH-(1-5) indicate GPR173 is another factor that may con-
tribute to the development of the HPG axis. Future studies will
need to verify the physiological significance of GnRH-(1-5) acti-
vating GPR173 during embryogenesis in addition to its role in
the adult since our initial studies indicate GnRH-(1-5) plays other
roles in reproductive biology.
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